Patent Application
20170143837
The present invention relates to a composition comprising a cationic molecular transporter and an anionic physiologically active material for skin penetration, in particular, for delivering the physiologically active material into the epidermis layer and a part of the dermis layer.
A cell is a basic unit of all living organisms, and is composed of the cytoplasm in which intracellular organelles are present and the cell membrane which protects the cytoplasm as well as separates it from the environment. Since the cell membrane is a selectively permeable barrier composed of a phospholipid bilayer and proteins of fluid state distributed in the bilayer in mosaic, it limits the passage of many useful therapeutic agents. Especially, hydrophilic molecules, highly charged molecules of low molecular weights and macromolecules such as peptides and oligonucleotides, e.g., nucleic acid or gene, cannot be transported across the cell membrane. Although special methods for transporting the molecules into cells have been developed (see [S. Futaki, Adv. Drug Delivery Rev., 2005, 57, 547-558] and [P. A. Wender, et al., Adv. Drug Delivery Rev., 2008, 60, 452-472]), they have raised many problems including cytotoxicity.
In the meantime, a number of molecular transporters for delivering physiologically active molecules across biological membranes have been developed (see [S. K. Chung, et al., Int. J. Pharmaceutics, 2008, 354, 16-22]; [K. K. Maiti, et al., Angew. Chem. Int. Ed., 2007, 46, 5880-5884]; [K. K. Maiti, et al., Angew Chem. Int. Ed., 2006, 45, 2907-2912]; and Korean Patent Nos. 10-0578732, 10-0699279, 10-0849033 and 10-1021078).
However, no attempt has been made to deliver water-soluble anionic physiologically active materials into the skin by using such molecular transporters. In order to deliver physiologically active materials having a phosphate group or a carboxylate group such as ascorbic acid phosphate or salicylic acid known as non-steroidal anti-inflammatory drugs into the skin, the present inventors have prepared an ionic complex through ionic bonding of physiologically active materials and known molecular transporters at a specific ratio, and found that the prepared ionic complex can enhance skin permeability, and thus accomplished the present invention.
It is an object of the present invention to provide a composition for skin penetration, which is for delivering a physiologically active material into the skin.
In accordance with one aspect of the present invention, there is provided a composition for skin penetration, comprising an ionic complex in which a cationic compound of any one selected from the following compounds represented by formulae (1) to (4) and an anionic physiologically active material are combined through ionic bonding, the composition being used for delivering the physiologically active material into the skin:
wherein
R1 and R2 are each independently H, C1-C6 alkyl, C6-C12 aryl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 heteroalkyl, —(CH2)mNHR′, —(CH2)1CO2R″, —COR′″, —SO2R″″, or a physiologically active material to be transported, where R′, R″, R′″ and R″″ are each independently H, C1-C6 alkyl, C6-C12 aryl C1-C6 alkyl, C3-C8 cycloalkyl, or C3-C8 heteroalkyl, m is an integer in the range of 2 to 5, and 1 is an integer in the range of 1 to 5;
and
n is an integer in the range of 1 to 12.
The composition according to the present invention has an excellent effect of transporting molecules having difficulty in passing through cell membranes or skin layers, e.g., ascorbic acid phosphate, aspirin, water-soluble anionic physiologically active materials, into the skin, thus may be effectively used for delivering physiologically active materials into the skin.
The above and other objectives and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, in which:
In accordance with one aspect of the present invention, there is provided a composition for skin penetration, comprising an ionic complex in which a cationic compound of any one selected from the following compounds represented by formulae (1) to (4) and an anionic physiologically active material are combined through ionic bonding, the composition being used for delivering the physiologically active material into the skin:
wherein
R1 and R2 are each independently H, C1-C6 alkyl, C6-C12 aryl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 heteroalkyl, —(CH2)mNHR′, —(CH2)1CO2R″, —COR′″, —SO2R″″, or a physiologically active material to be transported, where R′, R″, R′″ and R″″ are each independently H, C1-C6 alkyl, C6-C12 aryl C1-C6 alkyl, C3-C8 cycloalkyl, or C3-C8 heteroalkyl, m is an integer in the range of 2 to 5, and 1 is an integer in the range of 1 to 5;
and
n is an integer in the range of 1 to 12.
Hereinafter, the present invention is described in more detail.
In an embodiment of the present invention, the ionic complex comprises a cationic compound.
The cationic compound may be any one of the compounds represented by the above formulae (1) to (4), and is used as a molecular transporter (see Korean Patent Nos. 10-0578732, 10-0699279, 10-0849033 and 10-1021078).
As shown in the above formulae (1) to (4), the cationic compound has a structure in which guanidine or arginine group having side chains of a variety of length is introduced into sugar or sugar-like backbone in linear or branch form, thereby exhibiting water solubility and excellent biomembrane permeability. Accordingly, the cationic compound can easily pass through the cell membrane and skin layer in the form of ionic complex with various anionic physiologically active materials such as diagnostic reagents, medicines, fluorescent materials, etc.
The compound of formula (1) has a structure in which 1 to 8 guanidine groups are introduced into the hydroxyl end of sugar alcohol derivatives, wherein desired functional groups can be introduced in high density into the backbone by using branches of dendrimer form. According to one embodiment of the present invention, n can be an integer in the range of 1 to 12 in the compound of formula (1). Preferably, the compound of formula (1) can be alditol derivatives or salts thereof having a steric conformation of sorbitol, mannitol or galactitol, for example.
In the compound of formula (2), n can be an integer in the range of 1 to 12. More preferably, the compound of formula (2) can be sorbitol derivatives or salts thereof having eight (8) guanidine groups introduced thereinto.
In the compound of formula (3), n can be an integer in the range of 1 to 12. More preferably, the compound of formula (3) can be sorbitol derivatives or salts thereof having six (6) guanidine groups introduced thereinto.
The compound of formula (4) can be arginine (in case n is 1) or an arginine oligomer (in case n is an integer in the range of 2 to 12). Preferably, the compound of formula (4) can be an arginine oligomer wherein n is an integer in the range of 6 to 8.
In an embodiment of the present invention, the ionic complex comprises an anionic physiologically active material.
The anionic physiologically active material may be a water-soluble molecule including a carboxylic acid group (—CO2H), a phosphate group (—OP(O)(OH)2) or a sulfonic acid group (—SO3H). Preferably, the anionic physiologically active material can be selected from the group consisting of ascorbic acid phosphate, vitagen, inositol phosphate (IP), uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), acetylsalicylic acid, 4-aminobenzoic acid (4-AB), hyaluronic acid, dextran sulfate and a combination thereof.
In addition, the anionic physiologically active material can be linked to a fluorescent material selected from the group consisting of fluorescein (FITC), dansyl (5-dimethylamino-1-naphthalene sulfonyl), rhodamine and a combination thereof.
According to one embodiment of the present invention, the anionic physiologically active material can be selected from the following materials:
According to one embodiment of the present invention, the ionic complex is characterized in that the cationic compound and the anionic physiologically active material are combined through ionic bonding at a ratio of 1:1 to 4:1 on the basis of electric charges. The ratio of electric charges between the cationic molecular transporter compound and the anionic physiologically active material is critical to the manufacture of ionic complex for delivering molecules. When the ratio of cationic molecular transporter:anionic physiologically active material is 1:1 or higher, the formation of ionic complex with the substrate results in appropriate number of guanidine groups per molecule, which enhances cell permeability. When the ratio is 4:1 or lower, the competitive penetration through the cell membrane of the surplus molecular transporters in a free form, which are not involved in the formation of ionic complex with the substrate, can be prevented. As a result, the penetration rate of ionic complex may be increased and the efficiency of delivering a physiologically active material (substrate) may be improved.
Therefore, the ionic complex of the present invention in which the cationic compound is combined with the anionic physiologically active material through ionic bonding at a ratio of 2:1 on the basis of electric charges is preferred (see
The composition for skin penetration according to the present invention is characterized by penetrating into the skin up to the depth of 125 to 200 μm, preferably, up to the depth of 150 to 200 μm. The depth corresponds to the stratum corneum, whole viable epidermis layer and the upper part of dermis layer of the skin. Therefore, the composition for skin penetration according to the present invention can penetrate into the cell or under the skin, e.g., between the epidermis layer and the dermis layer, to deliver physiologically active materials (see Test Example 2 and
The following Examples are intended to further illustrate the present invention without limiting its scope.
Vitagen (99 mg, 0.316 mmol) was dissolved in a mixture of dimethylformamide and water (2.5:1 (v/v)) (2 mL), and then fluorescein-5-isocyanate (160 mg, 0.418 mmol) and triethylamine (300 μL, 2.158 mmol) were added thereto. The mixture was stirred at room temperature for 1 day. After completion of the reaction, the mixture was concentrated under a reduced pressure and then immediately purified by column chromatography (chloroform:ethanol:acetic acid=16:3:1 to dichloromethane:methanol=1:1) followed by ion exchange column chromatography using DOWEX 50WX8-400 ion exchange resin. The resultant was added with 1N NaOH to adjust the pH to 8-10, and then lyophilized to obtain the title compound (240 mg) as a yellow powder.
4-Aminobenzoic acid (50 mg, 0.3308 mmol) was dissolved in a mixture of tetrahydrofuran and ethanol (3:2 (v/v)) (5 mL), and then fluorescein-5-isocyanate (154 mg, 0.397 mmol) and triethylamine (69 μL, 0.4962 mmol) were added thereto. The mixture was stirred at room temperature for 1 day. After completion of the reaction, the mixture was concentrated under a reduced pressure and then immediately purified by column chromatography (dichloromethane:methanol=10:1) to obtain the title compound (145 mg) as a yellow powder.
<1-1> Preparation of Ionic Complex Comprising Cationic Compound Having Sorbitol Backbone with Eight (8) Guanidine Groups and Vitagen-FITC
The cationic compound of formula (2) according to the present invention, having sorbitol backbone with eight (8) guanidine groups (+8; one positive charge per guanidine group) (hereinafter referred to as “sorbitol-based G8 molecular transporter” or “SG8”), was prepared by the process described in Example 1 of Korean Patent No. 10-0699279. Next, the prepared SG8 (52 mg, 30 μmol) was dissolved in 500 μL of triple distilled water to obtain cationic stock solution.
Vitagen-FITC (−1; one negative charge for one phosphate) (84 mg, 120 μmol) obtained in Preparation Example 1 was dissolved in 2 mL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “SG8-vitagen-FITC”.
<1-2> Preparation of Ionic Complex Comprising SG8 and myo-inositol-1P-FITC
A cationic stock solution containing SG8 was prepared according to the process described in Example <1-1>.
myo-inositol-1P-FITC (hereinafter referred to as “IPF”) (−1; one negative charge for one phosphate) (92 mg, 120 μmol) was dissolved in 2 mL of triple distilled water to obtain an anionic stock solution (K. C. Seo et al. Journal of Carbohydrate Chemistry, 2007, 26, 305-327).
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “SG8-IPF”.
<1-3> Preparation of Ionic Complex Comprising SG8 and UDP-carba-GlcNAc-FITC (UDPF)
A cationic stock solution containing SG8 was prepared according to the process described in Example <1-1>.
UDP-carba-GlcNAc-FITC (hereinafter referred to as “UDPF”) (−2; two negative charges for two phosphates) (66 mg, 60 μmol) was dissolved in 1 mL of triple distilled water to obtain an anionic stock solution (K. C. Seo et al. Chemical Communications, 2009, 1733-1735).
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “SG8-UDPF (2:1)”.
<1-4> Preparation of Ionic Complex Comprising SG8 and UDPF
The procedure of Example <1-3> was repeated except that the cationic compound and the anionic physiologically active material were mixed at a ratio of 1:1 on the basis of electric charges to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 1:1 on the basis of electric charges.
The prepared ionic complex was called “SG8-UDPF (1:1)”.
<1-5> Preparation of Ionic Complex Comprising SG8 and UDPF
The procedure of Example <1-3> was repeated except that the cationic compound and the anionic physiologically active material were mixed at a ratio of 4:1 on the basis of electric charges to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 4:1 on the basis of electric charges.
The prepared ionic complex was called “SG8-UDPF (4:1)”.
<2-1> Preparation of Ionic Complex Comprising Cationic Compound Having Sorbitol Backbone with Six (6) Guanidine Groups and Vitagen-FITC
The cationic compound of formula (3) according to the present invention, having sorbitol backbone with six (6) guanidine groups (+6; one positive charge per guanidine group) (hereinafter referred to as “sorbitol-based G6 molecular transporter” or “SG6”), was prepared by the process described in Example 8 of Korean Patent No. 10-0699279. Next, the prepared SG6 (40 mg, 30 μmol) was dissolved in 500 μL of triple distilled water to obtain cationic stock solution.
Vitagen-FITC (63 mg, 90 μmol) obtained in Preparation Example 1 was dissolved in 1.5 mL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “SG6-vitagen-FITC”.
<2-2> Preparation of Ionic Complex Comprising SG6 and IPF
A cationic stock solution containing SG6 was prepared according to the process described in Example <2-1>.
IPF (69 mg, 90 μmol) prepared by the process described in Example <1-2> was dissolved in 1.5 mL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “SG6-IPF”.
<2-3> Preparation of Ionic Complex Comprising SG6 and UDPF
A cationic stock solution containing SG6 was prepared according to the process described in Example <2-1>.
UDPF (50 mg, 45 μmol) prepared by the process described in Example <1-3> was dissolved in 750 μL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “SG6-UDPF”.
<3-1> Preparation of Ionic Complex Comprising Arginine-Octamer and Vitagen-FITC
The cationic compound of formula (4) according to the present invention, arginine-octamer (hereinafter referred to as “ARG8”) (n=8; +8), was obtained from Peptron Inc. Next, ARG8 (61 mg, 30 μmol) was dissolved in 500 μL of triple distilled water to obtain cationic stock solution.
Vitagen-FITC (84 mg, 120 μmol) obtained in Preparation Example 1 was dissolved in 2 mL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “ARG8-vitagen-FITC”.
<3-2> Preparation of Ionic Complex Comprising ARG8 and IPF
A cationic stock solution containing ARG8 was prepared according to the process described in Example <3-1>.
IPF (92 mg, 120 μmol) prepared by the process described in Example <1-2> was dissolved in 2 mL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “ARG8-IPF”.
<3-3> Preparation of Ionic Complex Comprising ARG8 and UDPF
A cationic stock solution containing ARG8 was prepared according to the process described in Example <3-1>.
UDPF (66 mg, 60 μmol) prepared by the process described in Example <1-3> was dissolved in 1 mL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “ARG8-UDPF”.
<3-4> Preparation of Ionic Complex Comprising ARG8 and 4-ABF
A cationic stock solution containing ARG8 was prepared according to the process described in Example <3-1>.
4-ABF (−1; one negative charge for one carboxylate) (65 mg, 120 μmol) obtained in Preparation Example 2 was dissolved in 2 mL of triple distilled water containing 10% DMSO to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “ARG8-4-ABF”.
<4-1> Preparation of Ionic Complex Comprising Arginine-Hexamer and Vitagen-FITC
The cationic compound of formula (4) according to the present invention, arginine-hexamer (hereinafter referred to as “ARG6”) (n=6; +6), was obtained from Peptron Inc. Next, ARG6 (46 mg, 30 μmol) was dissolved in 500 μL of triple distilled water to obtain cationic stock solution.
Vitagen-FITC (63 mg, 90 μmol) obtained in Preparation Example 1 was dissolved in 1.5 mL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “ARG6-vitagen-FITC”.
<4-2> Preparation of Ionic Complex Comprising ARG6 and IPF
A cationic stock solution containing ARG6 was prepared according to the process described in Example <4-1>.
IPF (69 mg, 90 μmol) prepared by the process described in Example <1-2> was dissolved in 1.5 mL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “ARG6-IPF”.
<4-3> Preparation of Ionic Complex Comprising ARG6 and UDPF
A cationic stock solution containing ARG6 was prepared according to the process described in Example <4-1>.
UDPF (50 mg, 45 μmol) prepared by the process described in Example <1-3> was dissolved in 750 μL of triple distilled water to obtain an anionic stock solution.
The obtained anionic stock solution was slowly added to the cationic stock solution, and the mixture was stirred for 2-3 hours until the turbid mixture solution became clear. The mixture was lyophilized to obtain an ionic complex comprising cationic compound:anionic physiologically active material at a ratio of 2:1 on the basis of electric charges.
The prepared ionic complex was called “ARG6-UDPF”.
In order to confirm the cell membrane permeability of the ionic complexes prepared in the above Examples, the fluorescence of FITC-labeled physiologically active material (substrate) was measured by Confocal Laser Scanning Microscope (Olympus FV1000).
First, HeLa cells (ATCC® CCL-2™) were cultured in a dish plate. The cells were stabilized for 24 hours by using DMEM (Dulbecco's modified Eagle's medium) containing 10% fetal bovine serum before culturing on a serum-free medium for 24 hours to starve the cells. Thereafter, the cells were treated with the ionic complexes prepared in Examples 1-1 to 4-3 at a concentration of 48 μM (concentration of substrate) for 1 hour at 37° C. After the cells were washed with PBS (phosphate buffer solution) 5 times, the permeability through the cell membrane was immediately observed with a confocal microscope. In this case, each of vitagen-FITC, IPF, UDPF and 4-ABF (substrate) was used as a control.
An Ar laser (488 nm) was used for the excitation of fluorescence material and the cells were observed at 60× magnification. The results are shown in
As shown in
The above results indicate that when the ratio of molecular transporter (cation) is too low, the number of guanidine groups per molecule becomes relatively low due to the formation of ionic complex with substrate, which results in low cell penetration. Meanwhile, when the ratio of molecular transporter is too high, the surplus molecular transporters in a free form, which are not involved in the formation of ionic complex with substrate, penetrate the cell membrane competitively, which decreases the penetration rate of ionic complex.
As shown in
As shown in
As shown in
As shown in
ARG8-vitagen-FITC ionic complex weighed in an amount of 16 mg of vitagen-FITC based on substrate, among 26 mg of ARG8-vitagen-FITC ionic complex prepared in Example <3-1>, was dissolved in 84 μL of water, and mixed with 300 mg of polyethylene glycol (PEG) 400 to prepare 4% sample solution.
Each of SG8-vitagen-FITC ionic complex prepared in Example <1-1> and ARG8-4-ABF ionic complex prepared in Example <3-4> was used to prepare each of 4% sample solution, according to the process described above.
Four-week old BALB/c nude mice were anesthetized with gas, and 50 μL of each sample solution as prepared above was applied to the skin of the femoral region of the hind leg in an area of 1 cm×1 cm. The mice were placed in a dark room under anesthetic condition for 3 hours. After washing the sample applied to the leg with distilled water and 70% ethanol, and the mice were euthanized with carbon dioxide. The dermal tissue of the femoral region was exfoliated, placed on a slide glass, and fixed with cover slip. Transdermal permeability of each sample on the slide glass was observed with Two-photon Laser Scanning Microscope (Leica), and femto-second laser (960 nm) was used for the excitation of fluorescence material. The subcutaneous tissue was continuously photographed at an interval of 2 μm depth, and the images of representative depth (45 μm and 90 μm) were observed.
Furthermore,
As shown similarly in
Furthermore, the results of transdermal penetration measured by Two-photon Laser Scanning Microscope (Leica) show that the fluorescence-labeled physiologically active material penetrated into the depth of at least 125 to 200 μm, which corresponds to the stratum corneum, whole viable epidermis layer and the upper part of dermis layer of the skin.
As a result, it is confirmed that the ionic complex prepared according to the present invention exhibits an excellent permeability to the cell membrane and a superior transdermal penetration. Accordingly, the ionic complex of the present invention can be effectively used for delivering water-soluble anionic physiologically active materials into the cell or under the skin (viable epidermis layer and dermis layer).
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2014-0079931 | Jun 2014 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2015/001574 | 2/16/2015 | WO | 00 |
